ClinicalTrials.gov
public full text
Public Domain
PGL5001 Proof of Concept Study in Inflammatory Endometriosis
This is a prospective, three-part (Part A1, Part A2 and Part B),Phase II study investigating the efficacy, safety, pharmacokinetics and pharmacodynamics of the JNK inhibitor PGL5001 orally administered for up to 5 months with concomitant DMPA administration for the treatment of laparoscopically diagnosed inflammatory endometriosis. The part A1 is open-label, the parts A2 and B are double-blind. The target population will be women of reproductive age and suffering from newly diagnosed peritoneal and/or ovarian endometriosis.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- An Overview of Endometriosis and Potential Pharmacogenetic Targets#233290
- Study to Investigate the Efficacy of a Non-hormonal Drug Against Endometriosis Associated Pelvic Pain#836810
- Use of Rosiglitazone in the Treatment of Endometriosis#1113529
- Pilot Study of the IL-1 Antagonist Anakinra for the Treatment of Endometriosis Related Symptoms#1127967
- PBMC-derived FGF, PDGF, VEGF and GM-CSF secretion in endometriosis: a case–control in vitro study.#295221
Record · ID 1073445
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive